The third highly cited study, Localized and Diffuse Tenosynovial Giant Cell Tumor (Previously TGCT/PVNS) (16), published by F. Gouin from CHU de Nantes in 2016, reaffirmed complete surgical resection as first-line treatment, emphasizing more aggressive approaches for diffuse TGCT and the therapeutic potential of CSF-1R inhibitors. This evidence concerns the gene CSF1R and tenosynovial giant cell tumor, diffuse type.